Stay updated on Doxorubicin-Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Doxorubicin-Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Doxorubicin-Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    Site revision label updated from v3.5.0 to v3.5.2. This appears to be a build/metadata change and does not affect study content or user interactions on the page.
    Difference
    0.0%
    Check dated 2026-04-16T11:00:36.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    18 days ago
    No Change Detected
  4. Check
    33 days ago
    Change Detected
    Summary
    The site revision was updated to v3.5.0 and the previous v3.4.3 revision was removed.
    Difference
    0.0%
    Check dated 2026-03-18T18:06:22.000Z thumbnail image
  5. Check
    40 days ago
    Change Detected
    Summary
    Revision: v3.4.3 updates the site's version label. No visible changes to study details or patient-facing information.
    Difference
    0.0%
    Check dated 2026-03-11T15:14:53.000Z thumbnail image
  6. Check
    68 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2 and removed the prior operating-status notice (Revision: v3.4.1). To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-11T05:55:35.000Z thumbnail image
  7. Check
    75 days ago
    Change Detected
    Summary
    Added a site-wide notice about government funding affecting updates and the NIH Clinical Center's status. The page revision was updated from v3.4.0 to v3.4.1.
    Difference
    0.4%
    Check dated 2026-02-04T04:28:51.000Z thumbnail image
  8. Check
    82 days ago
    Change Detected
    Summary
    A new 'Show glossary' toggle is added, along with footer metadata showing 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and 'Revision: v3.4.0'. The deletions remove older wording/variants ('Last Update Submitted that met QC Criteria', 'No FEAR Act data', 'Revision: v3.3.4'), reflecting a minor UI update and data-label cleanup. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-01-28T02:08:10.000Z thumbnail image

Stay in the know with updates to Doxorubicin-Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Doxorubicin-Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial page.